Tri Locum Partners LP X4 Pharmaceuticals, Inc Transaction History

Tri Locum Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.03 - $2.02 $2.21 Million - $4.34 Million	2,147,557 Added 52.38%	6,247,500 $6.81 Million
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $181,596 - $551,432	221,459 Added 5.71%	4,099,943 $7.95 Million
Q1 2023 May 15, 2023	BUY	$0.8 - $1.22 $137,573 - $209,799	171,967 Added 4.64%	3,878,484 $3.37 Million
Q4 2022 Feb 14, 2023	BUY	$0.69 - $2.21 $829,732 - $2.66 Million	1,202,511 Added 48.02%	3,706,517 $3.67 Million
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.71 $681,478 - $1.31 Million	765,706 Added 44.05%	2,504,006 $4.28 Million
Q2 2022 Aug 15, 2022	BUY	$0.88 - $1.91 $18,225 - $39,558	20,711 Added 1.21%	1,738,300 $1.68 Million
Q1 2022 May 16, 2022	BUY	$1.48 - $2.58 $205,190 - $357,696	138,642 Added 8.78%	1,717,589 $3.01 Million
Q4 2021 Feb 14, 2022	BUY	$1.9 - $5.6 $3 Million - $8.84 Million	1,578,947 New	1,578,947 $3.62 Million

104

100M

213K

50.6K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $48.1M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.